Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/44360
Full metadata record
DC FieldValueLanguage
dc.contributor.authorIbrahim, W-
dc.contributor.authorWilde, M-
dc.contributor.authorCordell, R-
dc.contributor.authorSalman, D-
dc.contributor.authorRuszkiewicz, D-
dc.contributor.authorBryant, L-
dc.contributor.authorRichardson, M-
dc.contributor.authorFree, RC-
dc.contributor.authorZhao, B-
dc.contributor.authorYousuf, A-
dc.contributor.authorWhite, C-
dc.contributor.authorRussell, R-
dc.contributor.authorJones, S-
dc.contributor.authorPatel, B-
dc.contributor.authorAwal, A-
dc.contributor.authorPhillips, R-
dc.contributor.authorFowkes, G-
dc.contributor.authorMcNally, T-
dc.contributor.authorFoxon, C-
dc.contributor.authorBhatt, H-
dc.contributor.authorPeltrini, R-
dc.contributor.authorSingapuri, A-
dc.contributor.authorHargadon, B-
dc.contributor.authorSuzuki, T-
dc.contributor.authorNg, LL-
dc.contributor.authorGaillard, E-
dc.contributor.authorBeardsmore, C-
dc.contributor.authorRyanna, K-
dc.contributor.authorPandya, H-
dc.contributor.authorCoates, T-
dc.contributor.authorMonks, PS-
dc.contributor.authorGreening, N-
dc.contributor.authorBrightling, CE-
dc.contributor.authorThomas, P-
dc.contributor.authorSiddiqui, S-
dc.date.accessioned2019-06-11T15:03:16Z-
dc.date.available2019-06-11T15:03:16Z-
dc.date.issued2019-03-08-
dc.identifier.citationBMJ Open 2019;9:e025486en
dc.identifier.urihttps://bmjopen.bmj.com/content/9/3/e025486en
dc.identifier.urihttp://hdl.handle.net/2381/44360-
dc.description.abstractINTRODUCTION: Patients presenting with acute undifferentiated breathlessness are commonly encountered in admissions units across the UK. Existing blood biomarkers have clinical utility in distinguishing patients with single organ pathologies but have poor discriminatory power in multifactorial presentations. Evaluation of volatile organic compounds (VOCs) in exhaled breath offers the potential to develop biomarkers of disease states that underpin acute cardiorespiratory breathlessness, owing to their proximity to the cardiorespiratory system. To date, there has been no systematic evaluation of VOC in acute cardiorespiratory breathlessness. The proposed study will seek to use both offline and online VOC technologies to evaluate the predictive value of VOC in identifying common conditions that present with acute cardiorespiratory breathlessness. METHODS AND ANALYSIS: A prospective real-world observational study carried out across three acute admissions units within Leicestershire. Participants with self-reported acute breathlessness, with a confirmed primary diagnosis of either acute heart failure, community-acquired pneumonia and acute exacerbation of asthma or chronic obstructive pulmonary disease will be recruited within 24 hours of admission. Additionally, school-age children admitted with severe asthma will be evaluated. All participants will undergo breath sampling on admission and on recovery following discharge. A range of online technologies including: proton transfer reaction mass spectrometry, gas chromatography ion mobility spectrometry, atmospheric pressure chemical ionisation-mass spectrometry and offline technologies including gas chromatography mass spectroscopy and comprehensive two-dimensional gas chromatography-mass spectrometry will be used for VOC discovery and replication. For offline technologies, a standardised CE-marked breath sampling device (ReCIVA) will be used. All recruited participants will be characterised using existing blood biomarkers including C reactive protein, brain-derived natriuretic peptide, troponin-I and blood eosinophil levels and further evaluated using a range of standardised questionnaires, lung function testing, sputum cell counts and other diagnostic tests pertinent to acute disease. ETHICS AND DISSEMINATION: The National Research Ethics Service Committee East Midlands has approved the study protocol (REC number: 16/LO/1747). Integrated Research Approval System (IRAS) 198921. Findings will be presented at academic conferences and published in peer-reviewed scientific journals. Dissemination will be facilitated via a partnership with the East Midlands Academic Health Sciences Network and via interaction with all UK-funded Medical Research Council and Engineering and Physical Sciences Research Council molecular pathology nodes. TRIAL REGISTRATION NUMBER: NCT03672994.en
dc.description.sponsorshipThis research was funded by the Medical Research Council (MRC), Engineering and Physical Sciences Research Council (EPSRC) Stratified Medicine Grant for Molecular Pathology Nodes (Grant No. MR/N005880/1) and Midlands Asthma and Allergy Research Association (MAARA), and carried out at the University Hospitals of Leicester NHS Trust and University of Leicester, supported by the NIHR Leicester Biomedical Research Centre and the NIHR Leicester Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The authors would like to acknowledge the invaluable efforts of the research nurses responsible for the in-clinic sample collection as well as the input from the wider East Midlands Breathomics Pathology Node consortium (members list can be found at: https:// ember.le.ac.uk/web)en
dc.language.isoenen
dc.publisherBMJ Publishing Groupen
dc.relation.urihttps://www.ncbi.nlm.nih.gov/pubmed/30852546-
dc.rightsCopyright © the authors, 2019. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en
dc.subjectbreath analysisen
dc.subjectbreathlessnessen
dc.subjectobservational studyen
dc.subjectvolatile organic compounden
dc.titleAssessment of breath volatile organic compounds in acute cardiorespiratory breathlessness: a protocol describing a prospective real-world observational study.en
dc.typeJournal Articleen
dc.identifier.doi10.1136/bmjopen-2018-025486-
dc.identifier.eissn2044-6055-
dc.identifier.piibmjopen-2018-025486-
dc.description.statusPeer-revieweden
dc.description.versionPublisher Versionen
dc.type.subtypeJournal Article-
pubs.organisational-group/Organisationen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCESen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicineen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Cardiovascular Sciencesen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Infection, Immunity and Inflammationen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/Themesen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/Themes/Cardiovascularen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/Themes/Molecular & Cellular Bioscienceen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/Themes/Respiratory Scienceen
dc.dateaccepted2019-01-08-
Appears in Collections:Published Articles, Dept. of Cardiovascular Sciences

Files in This Item:
File Description SizeFormat 
e025486.full.pdfPublished (publisher PDF)1.2 MBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.